US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Monkeypox Concept

1,558.63

+6.830.44%

Number of Gainers:7

Number of Losers:4

Number of Flat:1

PE:- -

High:1,562.48

Open:1,551.79

Low:1,540.01

Close:1,551.80

Loading ...

Emergent BioSolutions falls -16.0%

Emergent BioSolutions Shares Down 14.2% After Quarterly Revenue Falls

THOMSON REUTERS

Gilead Sciences, Inc. : Oppenheimer Raises Target Price to $132 From $115

THOMSON REUTERS

SIGA to Host Business Update Call on March 11, 2025 Following Release of Fourth-Quarter and Full Year 2024 Financial Results

Tonix Pharmaceuticals presents new data on TNX-102 SL treatment

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at 7th International Congress on Controversies in Fibromyalgia

Emergent BioSolutions Shares Down 13.6% Premarket After Quarterly Revenue Falls

THOMSON REUTERS

Emergent BioSolutions Reports Strong 2024 Financial Turnaround

Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts

Emergent BioSolutions Reports 2024 Financial Results

Emergent BioSolutions Q4 Net Income USD -31.3 Million

THOMSON REUTERS

Emergent BioSolutions Inc: Outlook FY Total Revenues $750 Mln - $850 Mln

THOMSON REUTERS

Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results

Regeneron Gets Positive CHMP Opinion for Multiple Myeloma Drug

Gilead Sciences sets aside $200 million to resolve HIV drug probe

KRYS Gets Positive CHMP Opinion for EU Approval of Skin Disease Drug

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4583/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4583"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4583\",,,,,undefined,":{"symbol":"BK4583","market":"US","secType":"PLATE","nameCN":"Monkeypox Concept","latestPrice":1558.6333,"timestamp":1741294799999,"preClose":1551.8009,"halted":0,"volume":56355763,"delay":0,"changeRate":0.004403,"change":6.832397,"pbRate":3.824438,"amount":1567216713.575374,"amplitude":0.014477,"prevYearClose":1284.7982,"fiveDayClose":1511.4258,"twentyDayClose":1385.6759,"turnoverRate":0.020077,"marketCap":176585386358.5,"floatMarketCap":175792853063,"peRate":756.174276},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4583\",,,,,undefined,":{"symbol":"BK4583","high":1562.48,"amplitude":0.014477,"preClose":1551.8009,"low":1540.0138,"pbRate":"3.824438","latestPrice":1558.6333,"volume":56355763,"delay":0,"open":1551.7856,"prevYearClose":1284.7982,"prevWeekClose":1535.672,"prevMonthClose":1535.672,"prevQuarterClose":1284.7982,"fiveDayClose":1511.4258,"twentyDayClose":1385.6759,"sixtyDayClose":1305.8654,"secType":"PLATE","market":"US","turnoverRate":0.020077,"peRate":756.174276,"marketCap":176585386358.5,"floatMarketCap":175792853063,"timestamp":1741294799999,"nameCN":"Monkeypox Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4583\",,,,undefined,":{"bkCode":"BK4583","up":7,"down":4,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4583\",pageSize:16,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2516083756","title":"Emergent BioSolutions falls -16.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516083756","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516083756?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:51","pubTimestamp":1741099911,"startTime":"0","endTime":"0","summary":"Emergent BioSolutions (EBS) is down -16.0%, or -$1.09 to $5.74. Published first on TheFly – the ultimate source for real-time, market-moving breaki...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/emergent-biosolutions-falls-16-0?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/emergent-biosolutions-falls-16-0?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4583","EBS"],"gpt_icon":0},{"id":"2516672130","title":"Emergent BioSolutions Shares Down 14.2%  After Quarterly Revenue Falls","url":"https://stock-news.laohu8.com/highlight/detail?id=2516672130","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516672130?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:33","pubTimestamp":1741098817,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PN0DM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EBS","BK4583"],"gpt_icon":0},{"id":"2516676930","title":"Gilead Sciences, Inc. : Oppenheimer Raises Target Price to $132 From $115","url":"https://stock-news.laohu8.com/highlight/detail?id=2516676930","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516676930?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:15","pubTimestamp":1741094114,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nAZN3HPGL5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4578","IE00B7SZLL34.SGD","LU2089984988.USD","BK4566","LU1066053197.SGD","IE00BZ1G4Q59.USD","IE00B19Z3581.USD","LU1839511570.USD","LU0289739699.SGD","GILD","LU0234570918.USD","LU2087621335.USD","BK4585","IE00BKVL7J92.USD","BK4583","BK4568","LU2468319806.SGD","LU1585245621.USD","LU0058720904.USD","LU1066051498.USD","LU0109394709.USD","LU0320765992.SGD","BK4588","IE00BSNM7G36.USD","BK4532","LU1571399168.USD","IE0002270589.USD","IE00B19Z3B42.SGD","IE00B3T34201.USD","LU0889565916.HKD","BK4139","BK4550","LU1430594728.SGD"],"gpt_icon":0},{"id":"2516739516","title":"SIGA to Host Business Update Call on March 11, 2025 Following Release of Fourth-Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2516739516","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516739516?lang=en_us&edition=fundamental","pubTime":"2025-03-04 20:30","pubTimestamp":1741091400,"startTime":"0","endTime":"0","summary":"NEW YORK, March  04, 2025  (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and confere","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/04/3036372/9738/en/SIGA-to-Host-Business-Update-Call-on-March-11-2025-Following-Release-of-Fourth-Quarter-and-Full-Year-2024-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HST","BK4007","BK4585","BK4583","BK4218","SIGA","BK4588","BK4181"],"gpt_icon":0},{"id":"2516312673","title":"Tonix Pharmaceuticals presents new data on TNX-102 SL treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2516312673","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516312673?lang=en_us&edition=fundamental","pubTime":"2025-03-04 20:19","pubTimestamp":1741090767,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals (TNXP) presented data in an oral presentation at the 7th International Congress on Controversies in Fibromyalgia, held March ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tonix-pharmaceuticals-presents-new-data-on-tnx-102-sl-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tonix-pharmaceuticals-presents-new-data-on-tnx-102-sl-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4583","BK4139","TNXP"],"gpt_icon":0},{"id":"2516662075","title":"Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at 7th International Congress on Controversies in Fibromyalgia","url":"https://stock-news.laohu8.com/highlight/detail?id=2516662075","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516662075?lang=en_us&edition=fundamental","pubTime":"2025-03-04 20:00","pubTimestamp":1741089600,"startTime":"0","endTime":"0","summary":"TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable activity in treating fibromyalgia. TNX-102 SL demonstrated statistically significant improvement in the primary endpoint of reduction in fibromyalgia pain in two double-blind randomized Phase 3 studies. FDA Prescription Drug User Fee Act  goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia. If approved by FDA, it would become the first member of a new class of non-opioid analgesic drugs for fibromyalgia and the first new drug for treating fibromyalgia in more than 15 years","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tonix-pharmaceuticals-presented-data-analyses-120000851.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4135","BK4583","BK4139","TNXP","CNS"],"gpt_icon":1},{"id":"2516628839","title":"Emergent BioSolutions Shares Down 13.6% Premarket After Quarterly Revenue Falls","url":"https://stock-news.laohu8.com/highlight/detail?id=2516628839","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516628839?lang=en_us&edition=fundamental","pubTime":"2025-03-04 17:12","pubTimestamp":1741079528,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nL3N3PN0UQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4583","BK4139","EBS"],"gpt_icon":0},{"id":"2516615010","title":"Emergent BioSolutions Reports Strong 2024 Financial Turnaround","url":"https://stock-news.laohu8.com/highlight/detail?id=2516615010","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516615010?lang=en_us&edition=fundamental","pubTime":"2025-03-04 11:56","pubTimestamp":1741060577,"startTime":"0","endTime":"0","summary":"Emergent Biosolutions ( ($EBS) ) has released its Q4 earnings. Here is a breakdown of the information Emergent Biosolutions presented to its invest...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/emergent-biosolutions-reports-strong-2024-financial-turnaround?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/emergent-biosolutions-reports-strong-2024-financial-turnaround?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EBS","BK4583","BK4139"],"gpt_icon":0},{"id":"2516958616","title":"Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts","url":"https://stock-news.laohu8.com/highlight/detail?id=2516958616","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516958616?lang=en_us&edition=fundamental","pubTime":"2025-03-04 06:50","pubTimestamp":1741042206,"startTime":"0","endTime":"0","summary":"In the latest market close, Gilead Sciences  reached $115.99, with a +1.47% movement compared to the previous day. This move outpaced the S&P 500's daily loss of 1.76%. Meanwhile, the Dow experienced a drop of 1.48%, and the technology-dominated Nasdaq saw a decrease of 2.64%.The HIV and hepatitis C drugmaker's shares have seen an increase of 17.6% over the last month, surpassing the Medical sector's gain of 1.11% and the S&P 500's loss of 1.26%.The upcoming earnings release of Gilead Sciences will be of great interest to investors. The company's earnings per share  are projected to be $1.73, reflecting a 231.06% increase from the same quarter last year. In the meantime, our current consensus estimate forecasts the revenue to be $6.78 billion, indicating a 1.36% growth compared to the corresponding quarter of the prior year.The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research show","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gilead-sciences-gild-rises-market-225006380.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4550","BK4588","BK4578","LU0109394709.USD","LU1839511570.USD","LU0234570918.USD","LU0058720904.USD","IE00B7SZLL34.SGD","LU0289739699.SGD","LU2468319806.SGD","BK4583","LU2089984988.USD","GILD","BK4566","IE00B19Z3B42.SGD","IE0002270589.USD","LU1066053197.SGD","LU0320765992.SGD","LU2087621335.USD","IE00B19Z3581.USD","IE00B3T34201.USD","BK4532","BK4568","LU1585245621.USD","LU0889565916.HKD","LU1430594728.SGD","IE00BSNM7G36.USD","BK4585","LU1571399168.USD","BK4139","IE00BKVL7J92.USD","LU1066051498.USD","IE00BZ1G4Q59.USD"],"gpt_icon":0},{"id":"2516998661","title":"Emergent BioSolutions Reports 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2516998661","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516998661?lang=en_us&edition=fundamental","pubTime":"2025-03-04 05:51","pubTimestamp":1741038669,"startTime":"0","endTime":"0","summary":"The latest update is out from Emergent Biosolutions ( ($EBS) ). Emergent BioSolutions reported its financial results for the fourth quarter and ful...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/emergent-biosolutions-reports-2024-financial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/emergent-biosolutions-reports-2024-financial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EBS","BK4583"],"gpt_icon":0},{"id":"2516665796","title":"Emergent BioSolutions Q4 Net Income USD -31.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2516665796","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516665796?lang=en_us&edition=fundamental","pubTime":"2025-03-04 05:23","pubTimestamp":1741037004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nPLX6A2784:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EBS","BK4139","BK4583"],"gpt_icon":0},{"id":"2516661866","title":"Emergent BioSolutions Inc: Outlook FY Total Revenues $750 Mln - $850 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2516661866","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516661866?lang=en_us&edition=fundamental","pubTime":"2025-03-04 05:23","pubTimestamp":1741037004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nPLX6A2784:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EBS","BK4583","BK4139"],"gpt_icon":0},{"id":"2516666279","title":"Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2516666279","media":"GlobeNewswire","labels":["dataReport","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516666279?lang=en_us&edition=fundamental","pubTime":"2025-03-04 05:23","pubTimestamp":1741036980,"startTime":"0","endTime":"0","summary":"Fourth Quarter 2024 Total Revenues of $194.7 million; Full Year 2024 Total Revenues of $1.04 billionFourth Quarter 2024 Net Loss of $31.3 million, decrease in Net Loss of 37% versus prior yearFourth Q","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/03/3036066/33240/en/Emergent-BioSolutions-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4208","LU1878469433.USD","BK4583","EBS","AVA"],"gpt_icon":0},{"id":"2516944666","title":"Regeneron Gets Positive CHMP Opinion for Multiple Myeloma Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2516944666","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516944666?lang=en_us&edition=fundamental","pubTime":"2025-03-04 04:00","pubTimestamp":1741032000,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals, Inc. REGN obtained positive opinion for its pipeline candidate linvoseltamab from the European Medicines Agency’s  Committee for Medicinal Products for Human Use .The CHMP recommended conditional marketing authorization of linvoseltamab to treat adults with relapsed and refractory (R/R) multiple myeloma . The recommendation is specific to those who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.A final decision is expected in the coming months.Regeneron’s shares have lost 30.5% in the past year compared with the medical-biomedical genetics industry’s decline of 6.7%.Regeneron Pharmaceuticals Stock Price, Consensus and EPS Surprise. Regeneron Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Regeneron Pharmaceuticals, Inc. Quote. REGN’s oncology franchise got a boost with the European Commission","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/regeneron-gets-positive-chmp-opinion-200000419.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2089984988.USD","BMRN","FL","IE00BZ1G4Q59.USD","IE00B19Z3B42.SGD","LU1839511570.USD","LU2468319806.SGD","GILD","IE00BSNM7G36.USD","IE0002270589.USD","LU1974910355.USD","LU2362541513.USD","LU1917777945.USD","LU0234570918.USD","LU2237438978.USD","BK4007","BK4550","LU2362540622.SGD","LU0882574055.USD","LU2106854487.HKD","BK4087","LU0053666078.USD","LU0109394709.USD","IE00B19Z3581.USD","LU0320765992.SGD","03165","LU0889565916.HKD","LU1066051498.USD","LU1430594728.SGD","BK4094","LU2023250504.SGD","BK4532","BK4139","BK4585","LU2087621335.USD","LU0058720904.USD","IE00B3T34201.USD","BK4568","IE00B7SZLL34.SGD","LU0289739699.SGD","BK4583","LU1066053197.SGD","REGN","LU0823416689.USD","BK4566","RHHBY","LU0114720955.EUR","IE00BKVL7J92.USD","CHMP","LU1585245621.USD"],"gpt_icon":0},{"id":"2516653634","title":"Gilead Sciences sets aside $200 million to resolve HIV drug probe","url":"https://stock-news.laohu8.com/highlight/detail?id=2516653634","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516653634?lang=en_us&edition=fundamental","pubTime":"2025-03-04 00:18","pubTimestamp":1741018712,"startTime":"0","endTime":"0","summary":"Gilead Sciences sets aside $200 million to resolve HIV drug probeBy Luc Cohen NEW YORK, March 3 (Reuters) - Gilead Sciences GILD.O set aside $200 million for a potential settlement with federal prosec","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nL2N3PM0KH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","LU0889565916.HKD","LU1066051498.USD","BK4578","IE00BKVL7J92.USD","IE00B3T34201.USD","BK4550","IE00B19Z3581.USD","BK4585","BK4583","LU2468319806.SGD","GILD","BK4532","IE00B19Z3B42.SGD","LU0289739699.SGD","LU0320765992.SGD","LU1839511570.USD","LU0234570918.USD","LU0058720904.USD","LU1430594728.SGD","BK4566","IE00BZ1G4Q59.USD","LU1571399168.USD","LU2087621335.USD","IE00B7SZLL34.SGD","BK4588","IE00BSNM7G36.USD","BK4139","LU0109394709.USD","LU1066053197.SGD","LU1585245621.USD","IE0002270589.USD","LU2089984988.USD"],"gpt_icon":0},{"id":"2516656745","title":"KRYS Gets Positive CHMP Opinion for EU Approval of Skin Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2516656745","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516656745?lang=en_us&edition=fundamental","pubTime":"2025-03-03 23:59","pubTimestamp":1741017540,"startTime":"0","endTime":"0","summary":"Krystal BiotechKRYS announced that the European Medicines Agency'sCommittee for Medicinal Products for Human Use  has adopted a positive opinion recommending the approval of Vyjuvek for the treatment of wounds in patients with dystrophic epidermolysis bullosa . The intended DEB patient population includes those who have mutations in the COL7A1 gene starting from birth.DEB is a rare and severe monogenic disease that affects the skin and mucosal tissues. It is caused by one or more mutations in a gene called COL7A1. Vyjuvekis a non-invasive, topical, redosable gene therapy designed to deliver two copies of theCOL7A1 gene when applied directly to DEB wounds.In the past three months, shares of Krystal Biotech have plunged 18.3% compared with the industry’s 0.6% decline.More on CHMP’s Positive Opinion on Vyjuvek’s EU Approval. The positive CHMP opinion recommending the approval of Vyjuvekfor the DEB indication in the EU is based on the results of Krystal Biotech’s phase I/II GEM-1 and phase","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/krys-gets-positive-chmp-opinion-155900015.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LU2065171311.SGD","IE00BSNM7G36.USD","BMRN","LU1839511570.USD","LU2089984988.USD","BK4532","LU2087621335.USD","LU1066053197.SGD","IE00B19Z3581.USD","LU2065171402.SGD","BK4583","LU0889565916.HKD","IE00BZ1G4Q59.USD","BK4566","BK4588","GILD","IE00BKVL7J92.USD","BK4585","LU1585245621.USD","LU2065170008.USD","LU2065169927.USD","CHMP","KRYS","LU0234570918.USD","LU1571399168.USD","LU1066051498.USD","BK4568","LU0289739699.SGD","BK4578","LU0320765992.SGD","FOLD","IE0002270589.USD","IE00B7SZLL34.SGD","LU2468319806.SGD","LU0058720904.USD","BK4156","LU0109394709.USD","IE00B3T34201.USD","BK4087","BK4550","IE00B19Z3B42.SGD","LU1430594728.SGD"],"gpt_icon":0}],"pageSize":16,"totalPage":8,"pageCount":4,"totalSize":127}]}}